Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

14.58
-0.1950-1.32%
Volume:310.34K
Turnover:4.46M
Market Cap:1.37B
PE:-4.62
High:14.63
Open:14.63
Low:14.11
Close:14.77
52wk High:15.71
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.45
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:13.00
PE(LYR):-4.31

Loading ...

Replimune says RP2 plus nivolumab posts 19.1% response rate in phase 1 advanced solid tumor trial

Reuters
·
May 31

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

GlobeNewswire
·
May 31

Replimune Group - Rp1 Plus Nivolumab Achieves Median Overall Survival of 32.9 Months in Anti-Pd-1-Failed Melanoma

THOMSON REUTERS
·
May 30

Replimune reports 32.9-month median survival in IGNYTE trial of RP1-nivolumab in anti-PD-1-failed melanoma

Reuters
·
May 30

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

GlobeNewswire
·
May 30

Top News Today: Stocks Rise as Traders Await Iran Deal Confirmation

Dow Jones
·
May 30

Wedbush Adjusts Price Target on Replimune Group to $6 From $2, Maintains Neutral Rating

MT Newswires Live
·
May 30

Top Midday Gainers

MT Newswires Live
·
May 30

Why Penny Stock Replimune (REPL) Nearly Doubled Today

TIPRANKS
·
May 29

Replimune Shares Soar as FDA Reverses Course on Skin Cancer Drug Application

Stock News
·
May 29

Replimune Shares Surge 75% After Co Plans to Resubmit US Application for Skin Cancer Drug

THOMSON REUTERS
·
May 29

BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune

Reuters
·
May 29

Market Chatter: Replimune Plans to Resubmit Melanoma Therapy Application for FDA Approval

MT Newswires Live
·
May 29

Replimune Gets Third Try at FDA Approval After Makary Departure -- Update

Dow Jones
·
May 29

Replimune plans RP1 melanoma BLA resubmission after FDA talks

Reuters
·
May 29

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Reuters
·
May 29

Replimune Announces Planned Rp1 Bla Resubmission Following Productive Discussion With FDA

THOMSON REUTERS
·
May 29

Replimune Group - to Resubmit Rp1 Bla for Advanced Melanoma After Alignment With FDA

THOMSON REUTERS
·
May 29

Replimune Group - to Resubmit Rp1 Bla; FDA to Prioritize Review as Urgent

THOMSON REUTERS
·
May 29

BRIEF-Replimune Gets Third Try At FDA Approval After Makary Departure- WSJ

Reuters
·
May 29